IN THE NEWS
Homelessness increases risk of infection for injecting drug users
“ A new report from the Health Protection Agency shows that around three-quarters of injecting drug users (IDUs) have been homeless at some point. In addition, those who have been homeless have higher levels of injecting risk and associated infections, primarily through the sharing of needles and low standards of hygiene.”
Half of UK students at risk of silent time bomb disease students admit to ignorance of hepatitis C
“Results from a survey announced today show that half of British students may be exposing themselves to the deadly hepatitis C virus by engaging in ‘risky’ activities, such as sharing banknotes or straws when snorting drugs, getting a tattoo or piercing and sharing razors and toothbrushes.”
New hepatitis C antiviral CB5300 identified by Canopus BioPharma Researchers to enter clinical trial assessment
“Canopus BioPharma, Inc., a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that CB5300, its new antiviral drug candidate for treatment of Hepatitis C, will be entering into clinical trial assessment following successful in-vitro screening. The screening process was completed in September 2007 at a major contract research institute in Maryland, which resulted in a research report concluding that a family of molecules has been identified as potent inhibitors of flaviviruses.”
Inovio Biomedical's DNA vaccine delivery technology moves ahead in clinical trial for hepatitis C
“Inovio Biomedical, a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden, has begun enrolling patients for its Phase I/II clinical study of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The trial will test Tripep's proprietary DNA vaccine, ChronVac-C®, administered using Inovio's MedPulser® DNA Delivery System, in 12 subjects already infected with HCV. The trial is being conducted in Sweden at the world-renowned Karolinska Institute. The main purpose of the study is to show that the treatment is safe, but also to test if the treatment boosts patients' immune response to hepatitis C and its effects on virus replication. The market for therapies against hepatitis C infections is estimated at more than $2 billion and is expected to grow to more than $8 billion by 2015.”
Pharmasset gets FDA fast-track status on hepatitis C drug
“Pharmasset Inc. said Wednesday its R7128 treatment for chronic hepatitis C has received fast-track status from the U.S. Food and Drug Administration. The Princeton, N.J., pharmaceutical company, which specializes in oral therapeutics for the treatment of hepatitis B, hepatitis C and HIV, said it is currently enrolling a 28-day phase 1 clinical trial to evaluate R7128 in combination with Pegasys and Copegus in treatment-naive chronic hepatitis C patients. Fast-track status expedites the review of a drug candidate for a life-threatening condition with the potential to address an unmet medical need for the condition.”
4 transplant recipients get HIV from donor
Donor's infection is 1st such case in U.S. in 22 years
Four transplant recipients in Chicago contracted HIV from a high-risk organ donor whose infection went undetected in what hospital officials say is the first documented case of the virus being transmitted by organ donation in the U.S. in more than 20 years. The transplants occurred in January at three Chicago hospitals, but the patients did not learn until the last two weeks that they were infected with HIV and the virus for hepatitis C. One doctor said the news was “devastating" to the patients.”
The next hepatitis C blockbuster?
“The annual meeting of the American Association for the Study of Liver Diseases (AASLD) convened, and several drug developers -- from Roche to smaller development-stage participants such as Pharmasset -- presented data on their lead compounds for treating hepatitis C.”
Vertex hepatitis C drug effective in trial
“Vertex Pharmaceuticals experimental hepatitis C drug is more effective than existing treatments and works in half the time, but also causes significantly more side effects. Data to be presented at the Annual Meeting of the American Association of the Study of Liver Diseases show the drug, telaprevir, in combination with standard treatment, eradicated the hepatitis C virus in more than 60 percent of patients who took it as part of a 24-week treatment. Eradication of the virus is based on a measure known as sustained viral response, in which the virus remains at below detectable levels. Typically, not more than 50 percent of patients taking standard treatments see their virus eradicated and the typical length of treatment is 48 weeks.”
GlobeImmune announces presentation of additional phase 1b hepatitis C results at American Association for the Study of Liver Diseases 2007 annual meeting
“GlobeImmune, Inc. today announced that additional high dose results from the Company's randomized, placebo-controlled Phase 1b clinical trial evaluating GI-5005 as a treatment of chronic hepatitis C infection will be the subject of a poster presentation at the upcoming 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held in Boston at the John B. Hynes Convention Center from November 2-6, 2007.”
EACS: Studies underline the need for better hepatitis C treatment
“A French study presented at the Eleventh European AIDS Conference drew a stark contrast between HIV/hepatitis C (HCV)-coinfected patients for whom hepatitis treatment works and those it doesn't, and indicates that we should be offering treatment before significant liver damage has occurred - not because of it. And a Spanish study, which found a dismal prognosis for the HIV/HCV-coinfected with decompensated (end-stage) liver disease, reminds us why treatment (and better treatment) is needed.”
Phase II study shows that Nitazoxanide significantly improves response to standard of care in patients with chronic hepatitis C
“Romark Laboratories, a privately-owned biotechnology company, today announced results of a randomized phase II clinical trial showing that 79% of interferon-naive patients with chronic hepatitis C genotype 4 receiving nitazoxanide plus the standard of care had a sustained virologic response (SVR), or undetectable level of virus, 12 weeks following treatment, compared to 43% of patients receiving the standard of care without nitazoxanide. The patients treated with nitazoxanide also experienced no relapse and no more side effects than patients who received the standard of care. Interim results from this Phase II clinical trial will be presented on Tuesday November 6 in an oral presentation at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.”
Treatment with PEGASYS/COPEGUS gives hepatitis C patients a second chance to achieve a cure after not responding to PegIntron
“This Landmark Study Also Shows Response at 12 Weeks is a Powerful Predictor of Eventual Treatment Success. Roche announced final results from the REPEAT study, which demonstrate that treatment with once-weekly PEGASYS(R)(peginterferon alfa-2a(40KD)) and daily COPEGUS(R) (ribavirin) canachieve viral clearance in a number of patients who did not respond to initial treatment with PegIntron, another drug commonly used to treat hepatitis C.(1)”
Setback in search for hepatitis C treatment
“The effort to find an effective treatment for the millions of people thought to be infected with the “silent killer” hepatitis C virus has suffered a major setback. Although rates of infection have declined in the developed world because blood is now screened for this virus, it is estimated that about 0.4 per cent of the population in Britain remains infected with hepatitis C, a virus that is spread by blood and infects the liver. But most of these 2.5 million people do not know they have the disease, which can remain undetected for up to 20 years without major symptoms of liver disease but can eventually result in hardening of the liver (cirrhosis) and cancer.”
Glaxo starts Phase III hepatitis C Promacta tests
“GlaxoSmithKline Plc has started two new final-stage clinical trials of its experimental platelet-boosting drug Promacta in patients with hepatitis C, Europe's biggest drugmaker said on Monday. The Phase III studies will measure the ability of Promacta -- also known as eltrombopag -- to raise blood platelet counts enough to allow patients to receive antiviral therapy to treat their disease. Thrombocytopenia, or low-platelet levels, is a complicating factor in hepatitis C that can prevent patients receiving treatment.”
Gilead hepatitis drug may have heart issue-study
“Gilead Sciences Inc. said on Sunday an experimental hepatitis C treatment in very early stages of development showed encouraging antiviral activity, but a signal of a potential heart problem could put the drug on hold. Gilead said it has initiated a specific study to look at the potential cardiac risk, which is expected to be concluded before the end of the year.”
Study: Dry eye common symptom of hepatitis C infection
“Dry eye syndrome represents the most common ocular symptom of hepatitis C virus infection, according to a study by researchers in Germany. Investigators also found hepatitis C virus RNA in 10% of tear samples, emphasizing the potential of disease transmission through tears, the authors noted.”
Roche hepatitis C drug shows promise in mid-stage trial
“Roche said its experimental drug to treat chronic hepatitis C virus infection showed promising antiviral activity in a mid-stage trial when given in combination with two other drugs.”
OctoPlus says hepatitis C drug effective in study
“Dutch biotechnology firm OctoPlus said on Tuesday European safety and efficacy Phase IIa studies have shown an antiviral effect for its chronic hepatitis C drug Locteron. “A statistically significant dose response was observed in the study,” the company said in a statement, adding that the drug was tolerated at all doses.”
Hepatitis C treatment reduces the virus but serious liver problems may progress
“Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon. However, the treatment did not slow or prevent the progression of serious liver disease. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and were reported at the annual meeting of the American Association for the Study of Liver Disease in Boston on November 5, 2007. HALT-C is funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc.”
Consensus Interferon in hepatitis C is an option for those non-responsive to Peginterferon/Ribavrin:
“In a recent retrospective study of veterans, 12% of hepatitis C virus (HCV) subjects remained HCV ribonucleic acid (RNA) undetectable at least 3 months post-treatment with consensus interferon (Infergen) following prior treatment with peginterferon and ribavirin, researchers reported here at the 58th Annual Scientific Meeting of the American Association for the Study of Liver Disease (AASLD).”
Psychiatric disorders do not reduce effectiveness of hepatitis C treatment: presented at AASLD
“Although comorbid psychiatric disorders at initiation of treatment for hepatitis C virus (HCV) are a risk factor for mental adverse events, they do not negatively affect the duration of pegylated interferon alfa-2b plus ribavirin treatment, adherence to treatment, or sustained viral response, researchers reported here at the 58th Annual Scientific Meeting of the American Association for the Study of Liver Disease (AASLD). In clinical practice, patients infected with hepatitis C virus frequently have comorbid psychiatric disorders and are often drug users, noted Jean Philippe Lang, MD, Head of the Department of Psychiatry, Centre Hospitalier Erstein, Erstein, Cedex, France.”
Hepatitis C and decompensated Cirrhosis improve with combination therapy, individualized approach
“Identifying patients most likely to attain a sustained virologic response (SVR) requires an individualised approach in the treatment of patients with chronic hepatitis C and decompensated cirrhosis, Italian researchers reported here at the 58th Annual Scientific Meeting of the American Association for the Study of Liver Disease (AASLD). Patients infected with hepatitis C virus (HCV) genotype 2 who also have decompensated cirrhosis, for example, can still be treated successfully with pegylated interferon alfa-2b plus oral ribavirin, noted lead author Angelo Iacobellis, MD, Executive Physician, Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy. Accounting for viral genotype and early viral kinetics are the major pieces of the treatment puzzle.”
Some genotype 3 hepatitis C patients may require increased doses or longer treatment
“Actual treatment outcomes among patients with genotype 2 and 3 hepatitis C virus (HCV) are slightly lower than in those reported in interventional clinical trials, according to research from the Canadian Peginterferon alfa-2b prospective Optimal Weight-based dosing Response (POWeR) program, which was reported here at the 58th Annual Scientific Meeting of the American Association for the Study of Liver Disease (AASLD).”
“Real Life” that in clinical trials: presented at AASLD success treating chronic hepatitis C can match
“Successful treatment of patients with chronic hepatitis C virus (HCV) matching the outcomes of rigorous clinical trials can be achieved in routine clinical practice, according to research from the Canadian observational program pegylated interferon alfa-2b prospective Optimal Weight-based dosing Response (POWeR), discussed here at the 58th Annual Scientific Meeting of the American Association for the Study of Liver Disease (AASLD).”
Acute hepatitis C in a contemporary US cohort
“Acute hepatitis C virus (HCV) infection is often asymptomatic; thus, its epidemiology and natural history are difficult to define. Acute HCV infection was identified on the basis of HCV seroconversion within 1 year (n = 45), new anti-HCV seropositivity with clinical acute hepatitis (n = 21), or HCV strain sequencing after an iatrogenic exposure (n = 1).”
Hepatitis C: the disease no one's talking about
The disease is a ‘silent epidemic’ that is getting little public attention, state official says
“Ann Shindo takes to task the federal government for failing to confront hepatitis C in Oregon and across the country. “Remember when Reagan didn't say AIDS? That's where we are with hep C,” said Shindo, the coordinator of viral hepatitis prevention for the Oregon Department of Human Services. "It's (like) 1988, pal, and no one's talking about hep C.”
Infectious disease claims 666 in China in October
“Infectious diseases claimed 666 lives in China in October out of about 418,000 recorded cases, the Ministry of Health said here on Monday. Last month, more than 318,612 cases of A-Class and B-Class infectious diseases occurred and claimed 660 lives. Of the 98,661 cases of C-Class infectious diseases recorded, there were six fatalities.”
State OKs settlements for Oregon inmates with hepatitis C
“The state of Oregon has paid more than $300,000 to settle claims of 5 inmates who say they were denied adequate treatment for hepatitis C. The Salem Statesman Journal reports 4 of the inmates are dead, and a fifth is seriously ill at the Snake River Correctional Institution in Eastern Oregon. About 70% of new infections are a result of drug users sharing needles.”
Syringe scare: hundreds tested for HIV, Hepatitis
“CBS 2 HD has learned of a shocking case of medical negligence on Long Island. A doctor may have exposed hundreds of patients to potentially deadly diseases like AIDS and hepatitis -- all because he allegedly re-used needles.”
New York State Department of Health (NYSDOH) stops a world first U.S. - Egyptian collaborative study on hepatitis C and blood ozonation
“ Recently coming to light is the involvement of the New York State Department of Health (NYSDOH) in stopping a world-first U.S. - Egyptian collaborative study on hepatitis C in Egypt. According to one of its principals, Dr. Gerard Sunnen, the study, bringing together the Egyptian National Research Centre (NRC) and Medizone International, Inc., a US - based company, sought to evaluate new therapeutic options for stimulating natural immune factors in fighting the disease. “Blood ozonation is an innovative technique of interfacing blood with minuscule amounts of ozone/oxygen mixtures that enhance natural cytokine and interferon production for purposes of viral clearing. This process, if successful, could greatly reduce the cost of current treatments for hepatitis C,” states Dr. Sunnen. In 2002, the NYSDOH stopped the study. “It is a sad day for the some estimated 5 million Egyptian patients, and some 170 million worldwide,”ť he added.”
Regulus gets patent on hep C treatment
“Regulus Therapeutics, a joint venture of Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc., said Friday the U.S. Patent and Trademark Office issued the venture a patent covering methods for targeting the hepatitis C virus.”
L.A. Hepatitis C Summit promotes reliable syringe access for the first time
“At the Fifth Annual Hepatitis C Summit last week in Los Angeles, DPA raised awareness of the Disease Prevention Demonstration Project (DPDP), a program allowing over-the-counter syringe sales in registered pharmacies in Los Angeles County (and several other counties around the state). The DPDP was created by statewide legislation in 2004, and DPA supports implementation of the program in Los Angeles County.”
Medivir: initiation of a Phase IIa clinical trial with investigational hepatitis C Protease Inhibitor TMC435350
“Medivir announced today that, following the successful completion of a phase I study in both healthy volunteers and patients chronically infected with hepatitis C virus (HCV), the phase IIa study, TMC435350-C201, of the investigational hepatitis C (HCV) protease inhibitor TMC435350. The study will start shortly in Europe by Tibotec Pharmaceuticals Ltd., who are collaborating with Medivir on the development of TMC435350.”
Phynova group says phase I/II trial on hepatitis C drug candidate successful
“Phynova Group PLC said preliminary data from the phase I/II trials of its lead drug candidate PYN17, for treating chronic hepatitis C, successfully confirms its safety and tolerability. The company said the results show that PYN17 was well tolerated, with a low level of relatively minor adverse events identical to those seen with a placebo.”
Medivir: initiation of a Phase IIa Clinical Trial with investigational hepatitis C Protease Inhibitor TMC435350
“Medivir has announced that a Phase IIa study for its investigational hepatitis C protease inhibitor will start shortly in Europe by Tibotec Pharmaceuticals, who are collaborating with Medivir on the development of the drug.”
CLINICAL TRIALS, COHORT STUDIES, AND PILOT STUDIES
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.Pearlman BL, et al. Hepatology. 2007 Dec;46(6):1688-94.
Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Kanwal F, et al. Hepatology. 2007 Dec;46(6):1741-9.
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. McHutchison JG, et al. N Engl J Med. 2007 Nov 29;357(22):2227-36.
Liver retransplantation of patients with hepatitis C infection is associated with acceptable patient and graft survival. Ghabril M, et al. Liver Transpl. 2007 Dec;13(12):1717-27.
Pegylated Interferon Alfa-2a (40 kD) and Ribavirin in haemodialysis patients with chronic hepatitis C. van Leusen R, et al. Nephrol Dial Transplant. 2007 Nov 27 [Epub ahead of print]
Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Okanoue T, et al. Hepatol Res. 2008 Jan;38(1):27-36.
Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: Pilot study. Kornberg A, et al. J Gastroenterol Hepatol. 2007 Dec;22(12):2135-42.
High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Hsu CS, et al. Liver Int. 2007 Nov 19 [Epub ahead of print]
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Arase Y, et al. Intern Med. 2007;46(22):1827-32. Epub 2007 Nov 16.
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Veldt BJ, et al. Ann Intern Med. 2007 Nov 20;147(10):677-84. Summary for patients in:
Ann Intern Med. 2007 Nov 20;147(10):I47.
Differences in long-term outcome and prognostic factors according to viral status in patients with Hepatocellular Carcinoma treated by surgery. Kondo K, et al. J Gastrointest Surg. 2007 Nov 13 [Epub ahead of print]
Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Kita Y, et al. Metabolism. 2007 Dec;56(12):1682-8.
De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Martín-Santos R, et al. Aliment Pharmacol Ther. 2007 Nov 6 [Epub ahead of print]
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Dalgard O, et al. Hepatology. 2007 Nov 1 [Epub ahead of print]
Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Bruce RD, et al. Am J Drug Alcohol Abuse. 2007;33(6):869-74.
Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. Chen CH, Wang MH, et al. Am J Trop Med Hyg. 2007 Oct;77(4):747-52.
BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES
Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. Suzuki K, et al. Hepatol Res. 2007 Nov 16 [Epub ahead of print]
Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Mitsuyoshi H, et al. Hepatol Res. 2007 Nov 16 [Epub ahead of print]
Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Jeng JE, et al. Neoplasia. 2007 Nov;9(11):987-92.
Significant effect of hepatitis C virus specific CTLs on viral clearance in patients with type C chronic hepatitis treated with antiviral agents. Satake S, et al. Hepatol Res. 2007 Nov 22 [Epub ahead of print]
Evolution of hepatitis C virus infection under host factor influence in an ethnically complex population. Cursino-Santos JR, et al. Liver Int. 2007 Dec;27(10):1371-1378.
Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. Azzari C, et al. J Med Virol. 2008 Jan;80(1):65-71.
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Hora C, et al. Liver Int. 2007 Nov 1 [Epub ahead of print]
Mutations in the interferon sensitivity determining region (NS5A aa 2209-2248) in patients with hepatitis C 1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.Yen YH, et al. Aliment Pharmacol Ther. 2007 Oct 26 [Epub ahead of print]
Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. Bertino G, et al. Minerva Gastroenterol Dietol. 2007 Dec;53(4):305-9.
Spontaneous recovery in acute human HCV infection: functional T cell thresholds and relative importance of CD4 help. Smyk-Pearson S, et al. J Virol. 2007 Nov 28 [Epub ahead of print]
Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. Pereira FA, et al. J Med Virol. 2008 Jan;80(1):58-64
Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. Zhang Y, et al. Nov 26 [Epub ahead of print]
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. Tellinghuisen TL, et al. J Virol. 2007 Nov 21 [Epub ahead of print]
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Zeisel MBet al. Hepatology. 2007 Dec;46(6):1722-31.
Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Recher M, et al. Nat Med. 2007 Nov;13(11):1316-23. Epub 2007 Nov 4.
Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV). Jiménez-Hernández N, et al. Virus Res. 2007 Nov 1 [Epub ahead of print]
Long-term response to highly active antiretroviral therapy in human immunodeficiency virus and hepatitis C virus coinfected children: 6 years of follow-up. Micheloud D, et al. Pediatr Infect Dis J. 2007 Nov;26(11):1061-4.
Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. Stapleton JT, et al. HIV Clin Trials. 2007 Nov-Dec;8(6):429-36.
Analysis of severe hepatic events associated with Nevirapine-containing regimens : CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Torti C, et al. Drug Saf. 2007;30(12):1161-9.
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. Smit C, et al. J Acquir Immune Defic Syndr. 2007 Nov 1 [Epub ahead of print]
Comorbidities in older patients with HIV: a retrospective study. Magalhăes MG, et al. J Am Dent Assoc. 2007 Nov;138(11):1468-75.
COMPLEMENTARY AND ALTERNATIVE THERAPIES
Assessment of nutritional status of patients with hepatitis C virus-related liver cirrhosis. Kawabe N,
et al. Hepatol Res. 2007 Nov 16 [Epub ahead of print]
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Huang H, et al. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18666-70. Epub 2007 Nov 14.
Prevalence & risk factors for hepatitis C virus among pregnant women. Kumar A, et al. Indian J Med Res. 2007 Sep;126:211-5.
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. Page-Shafer K, et al. J Clin Microbiol. 2007 Nov 21 [Epub ahead of print]
Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. González V,
et al. Eur J Clin Microbiol Infect Dis. 2007 Nov 20 [Epub ahead of print]
Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil. Maresch C, et al. Transfusion. 2007 Nov 13 [Epub ahead of print]
Benchmarking self-reported practice regarding Scottish Executive guidance on hepatitis C-infected health care workers. Steiner M, et al. Occup Med (Lond). 2007 Dec;57(8):607-9. Epub 2007 Nov 13.
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. Marti Nez-Bauer E, et al. J Hepatol. 2007 Oct 12 [Epub ahead of print]
Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Grebely J, et al. Drug Alcohol Depend. 2007 Nov 8 [Epub ahead of print]
Syringe exchange programs. MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1164-7.
Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Hahn JA, et al. Drug Alcohol Depend. 2007 Oct 31 [Epub ahead of print]
Liver transplantation and quality of life: relevance of a specific liver disease questionnaire. Gotardo DR, et al. Liver Int. 2007 Nov 1 [Epub ahead of print]
Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy-relapse or re-infection? Arrais TC, et al J Med Virol. 2008 Jan;80(1):80-6.
Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. Vizzutti F, Arena U, et al. Liver Int. 2007 Dec;27(10):1379-88.
Bioelectrical impedance analysis for the evaluation of Hepatic Fibrosis in patients with chronic hepatitis C infection. Antaki F, et al. Dig Dis Sci. 2007 Nov 13 [Epub ahead of print]
Measurement of Ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Morello J, et al. Ther Drug Monit. 2007 Dec;29(6):802-806.
Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays. Engle RE, et al. J Med Virol. 2008 Jan;80(1):72-9.